PT - JOURNAL ARTICLE AU - Philipp Harter AU - Jalid Sehouli AU - Alexander Reuss AU - Klaus Baumann AU - Lars Hanker AU - Rainer Kimmig AU - Willibald Schröder AU - Alexander Burges AU - Martina Gropp-Meier AU - Christian Kurzeder AU - Sven Mahner AU - Ulrich Canzler AU - Hans-Joachim Lück AU - Werner Meier AU - Tanja Fehm AU - Andreas du Bois TI - Phase II Study Evaluating PegLiposomal Doxorubicin and Carboplatin Combination Chemotherapy in Gynecologic Sarcomas and Mixed Epithelial-Mesenchymal Tumors A Phase II Protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie Study Group (AGO-GYN 7) AID - 10.1097/IGC.0000000000000831 DP - 2016 Nov 01 TA - International Journal of Gynecologic Cancer PG - 1636--1641 VI - 26 IP - 9 4099 - http://ijgc.bmj.com/content/26/9/1636.short 4100 - http://ijgc.bmj.com/content/26/9/1636.full SO - Int J Gynecol Cancer2016 Nov 01; 26 AB - Background Gynecologic sarcomas are rare diseases with still undefined optimal treatment. Platinum and anthracyclines were reported as active agents in gynecologic sarcoma and carcinosarcoma. So far, data regarding the combination of carboplatin and pegylated liposomal doxorubicin for this patient population are missing.Methods This prospective single-arm multicenter phase II trial evaluated the efficacy of carboplatin AUC 6 in combination with pegylated liposomal doxorubicin 40 mg/m2 q28 in 40 patients with newly diagnosed or recurrent gynecologic sarcoma or carcinosarcoma.Results Twenty patients with carcinosarcoma and 20 patients with leiomyosarcoma or endometrial stromal sarcoma were included. The percentage of patients with grade 3/4 neutropenia was 50%, but we did not observe any febrile neutropenia. The rates of grade 1 and 2 palmo-plantar erythema were moderate with 25% and 10%, respectively. Response rate was 33.3%. The 12-month progression-free and overall survival times were 32.5% and 77.0%, respectively.Conclusions The combination of carboplatin and pegylated liposomal doxorubicin is feasible and has activity within the investigated study cohort.